California LifeSciences Industry

2017REPORT

Peter Claude

Partner,Pharmaceutical &Life SciencesAdvisory

PwC

Sara Radcliffe

President & CEO

California LifeSciences Association(CLSA)

Sincerely,

Jerry Brown

Governor ofCalifornia

Letter from the GovernorCalifornia has a unique history of innovation: from agriculture to the film industry to information technology tolife sciences. As a group, Californians have repeatedly devised new technologies, and better ways to use oldtechnologies, to solve some of the world’s most intractable problems.

As the birthplace of biotechnology, California prides itself on the innovation born in the life sciences in particular.Genomic technologies help us detect disease, while new therapies and devices help treat them. Biofuels provideclean, sustainable energy that will ease our dependence on foreign sources and help solve climate change. Digitalhealth technologies help prevent disease and give patients better tools to manage their conditions.

The California Life Sciences Association is an important partner in our efforts to foster a stronger biomedicalindustry and boost job growth in California. This state is committed to supporting this critical sector, botheconomically and through strong public policy. Life Sciences is a cornerstone of California’s economy and I lookforward to working with leaders in this sector as we continue to contribute to a healthier society, strengthen oureconomy and advance new medical technologies.

Sincerely,

Letter to StakeholdersWhen people envision a vibrant life sciences community, they think of California. It beginswith the state’s public and private research universities and institutes, which produce ahighly trained scientific workforce, invaluable insights into human biology and world-changing research.

In some cases, these breakthroughs might be developed into a product – a drug that targetsa cancer-driving protein, for example. A pharmaceutical, biotechnology or medical devicecompany licenses the intellectual property, or the researchers find investors and createtheir own start-up. Years and millions of dollars later, the treatment may enter the clinicand improve patient care.

California succeeds because the state’s political, academic and business leaders are committedto a strong life sciences ecosystem. Smart policy decisions have played a role in continuedsuccess. Because the state has long supported higher education, California produces morebiology and engineering PhDs than any other state.

In 2004, when national policy shifted away from stem cell research, California votersapproved Proposition 71, which funded the California Institute for Regenerative Medicine(CIRM). This commitment led to groundbreaking basic and translational research, acceleratingstem cell therapies into clinical trials and making California the epicenter for stem cellresearch.

By most measures, the California life sciences industry is strong and growing. There are3,040 life sciences companies, including industry-leading global corporations, entrepreneurialstartups and everything in-between. California’s life sciences industry directly employsmore than 287,000 people, generated $147.7 billion in revenue in 2015 and has 1,269medicines – and even more devices and diagnostics – in the pipeline to boost patient care.

This report lays out the many strengths that define the life sciences in California, but thework must continue. Few industries can do so much to improve quality of life. We mustcontinuously renew our commitment to these efforts.

DirectEmployment

Indirect and InducedEmployment

Total Direct, Indirect and Induced Jobs:

884,200

597,000287,200

Life Sciences Industryin California, 2015 (estimated)

Total revenueDirect employmentTotal wages and salariesAverage annual life sciences industry wageTotal NIH grants awarded (2016)Total venture capital investments (2016)Total biomedical exportsDirect federal taxesDirect state and local taxes

$147.7 billion287,200

$33.5 billion$116,484

$3.6 billion$4.4 billion$22 billion

$10.5 billion$5.1 billion

1

California’s life sciences community continues to grow, with3,040 life sciences companies – 192 more than the previousyear – producing new technologies and boosting the state’seconomy. In 2015, the Golden State’s life sciences industryemployed more than 287,000 people.  This highly trainedand diverse workforce helped develop novel drugs, devicesand diagnostics, while also exploring other applications,such as leveraging biotechnology to produce sustainableenergy.

Life sciences companies have been incredibly successful.As of September 7, 2016, 1,269 drugs from Californiacompanies were in the FDA pipeline. In 2015, 264 newdevices developed by California companies were approved.

In addition, these companies produced more than $147billion in revenue, received $4.4 billion in venture capitalfunding, drove $22 billion in exports and paid $15.6 billionin federal and California state and local taxes.

Academic excellence, forward-thinking public policy andthe commitment of thousands of entrepreneurs and businessleaders has translated into new ways to address some of theworld’s most severe medical conditions: cancer, hepatitis,HIV, rare diseases and many others. These efforts helppower our economy, support job creation and improve healthfor millions around the world.

California’s Unique Life Sciences Ecosystem

Top Life Sciences Employmentin California, 2011 -2015

2015 2014 2013 2012

ANNUALCOMPOUND

GROWTH

SOURCES: Bureau of Labor Statistics Quarterly Census of Employment and Wages;2012 Economic Census; BloombergSOURCES: Bureau of Labor Statistics Quarterly Census of Employment and Wages;

2012 Economic Census

CaliforniaNew YorkNew JerseyIndianaPennsylvaniaIllinoisMassachusettsMinnesotaNorth CarolinaFloridaTexasMichiganUtahWisconsinOhio

Biopharmaceutical and Medical Device Employmentby state, 2011-2015

2015 rankingby employment

Employment growth,2011-2015

Employees,change from 2011

122,53537,55636,83835,86635,53934,33033,41432,89731,49729,18126,72121,67518,42516,00015,804

7,702(-1,464)(-8,473)

695(-3,131)

2,2031,924(-124)1,7212,3461,7911,3243,691(-372)(-693)

-8%

6%

9%

-<1%

-19%

7%

7%

2%

6%

-4%

7%7%

25%-2%

-4%

3

7

1

2

45

6

8

10

9

11

1412

13 15

MedicalDevice andEquipment

Manufacturing

1,714

Biotechnology andPharmaceutical

1,326

Number of Life Sciences Companiesin California, 2015

TOTAL

3,040

Medical Devices,Instruments,

Diagnostics

0.1%

74,39474,64274,61674,549

Research &Development,

Testing Labs

3.7%

62,29064,00766,383

69,542

Wholesale Trade(e.g. distribution ofpharmaceuticals or

hospital equipment)

2.9%

45,79546,42448,38049,884

Biorenewables(e.g. organic compound

mfg., ethanol mfg.)

3.1%

3,3063,3203,3653,624

Biopharmaceuticals2.7%

44,24545,18747,17147,985

Academic Research1.7%

39,50940,19140,85041,617

2

Producing Drugs, Devices, Diagnostics andDigital Health Technologies

Even more importantly, the total number of therapies in clinicaltrials continues to grow, ultimately providing more choicesfor patients and physicians as they work to overcome disease.

One of the many strengths of California’s life sciencescommunity is its eagerness to embrace new ideas. The digitalhealth sector is only a few years old, but is showing tremendouspotential to improve care.

Innovative digital technologies can keep congestive heartfailure patients out of the hospital, help patients comply withtheir drug regimens, support treatment for PTSD and muchmore. California companies lead the nation in attractingventure capital (VC) investment for innovative digital healthtechnologies.

Great ideas often begin in academic labs as scientists researchhuman biology and look for better ways to diagnose andtreat disease: a new marker to track cancer progression; aunique molecule that controls an aberrant protein; a digitaldevice that helps patients better manage their heart disease.

California’s life sciences community does an excellent jobat moving these ideas out of labs, through various regulatoryprocesses and ultimately to patients. In 2016, Californiabiopharmaceutical companies had 404 therapies in the FDApipeline for cancer, 134 for infectious diseases and 129 forcentral nervous system disorders. Similarly, the state’smedical device sector saw 264 products successfully throughthe FDA: 10 premarket approvals (PMA), 250 510(k)clearances and four de novo’s.

Medical Device Approvalsby companies headquartered in California, 2015

SOURCE: EvaluateMedTech®, August 2016

PMA - First Approval

TOTAL: 264

10 250 4

510(k) Clearance De Novo

* 2016 data based on projection from the first two quarters

CaliforniaNew YorkMassachusettsTexasIllinois

Top 5 States for Digital Health VC Funding2015 vs. 2016*

2015 2016*InvestmentInvestment

$2.1B$540M

$346M$47M$117M

$1.6B$730M

$392M$231M$198M

California Medicines by Therapeutic AreaInvestigational New Drug (IND) products through Phase III clinical trials

Cardiovascular

Therapies in Pipeline TOTAL: 1,269

Miscellaneous

Genitourinary

Respiratory

Cancer

Infectious Diseases (incl. HIV)

Central Nervous System

Hormonal Systems/Nephrology*

Immune System

Musculoskeletal

Pain

Eye/Ear

Hematological

Gastrointestinal

Dermatology

Diagnostic/Imaging/Delivery

SOURCE: Biopharm Insight, INDs filed through Phase III, Sept. 7, 2016

*incl. Diabetes

404

134

129

70

100

69

52

41

60

53

43

39

44

16

11

4

Wearables/BiosensingConsumer Health, Wellness1

Digital Diagnostics, Devices, TherapiesCare Management, Administration2

Analytics/Big DataLife Sciences Tools3

Personalized MedicineOtherRemote Patient MonitoringTelemedicine

California Digital Health VC Investmentby category, 2016*

1 Includes consumer health information, enterprise wellness, healthcare consumerengagement and personal health tools and tracking

* 2016 data based on projection from the first two quarters

2 Includes the care coordination, general care management, hospital administration,physician practice management, population health management, hospital CRM andmarketing and EHR/clinical workflow categories3 Includes the life sciences commercialization tools and life sciences R&D tools categories

Investment$384M

$361M$312M

$189M$131M

$90M$61M$59M

$36M$20M

Bay Area**San Diego CountyLos Angeles CountyOrange CountySacramento Area***

** Includes Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara andSonoma counties

* 2016 data based on projection from the first two quarters

California Digital Health VC Investmentby region, 2015 vs. 2016*

*** Includes Sacramento, Butte, El Dorado, Nevada, Placer, Solano, Sutter, Yolo and Yuba counties

Investment Investment2015 2016*

$1.6B$53M

$375M$72M$2M

$1.4B$173M$68M

$0$0

SOURCE: Rock Health Digital Health Funding Database

3

Driving Economic GrowthCalifornia has a strong and diverse economy, powered byinformation technologies, agriculture, energy, tourism andthe life sciences. Second to life-saving products, excellentjobs may be the biomedical community’s greatestcontribution to the state. In 2015, California life sciencescompanies employed more than 287,000 people, a twopercent increase over 2014. These jobs ran the gamut fromacademic research to bioengineering to wholesale trade.

Even more impressive, the industry generated 597,000indirect and induced jobs, bringing the total to 884,200.In addition, the average wage for California life sciencesemployees topped $116,000 and total wages exceeded$33 billion.

While biomedical growth has been historically stronger inthe San Francisco Bay Area and San Diego, new,entrepreneurial companies are becoming more prevalentin Los Angeles, a trend that could bode well for the region(see Los Angeles insert).

Total Life SciencesEmployment by Clusteras a percent of the total, 2015

SOURCES: Bureau of Labor Statistics Quarterly Census of Employment and Wages; 2012 Economic Census

24%

2%

3%

13%

20%

15%

4%1% 4%

EMPLOYEES

* Includes Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara and Sonoma counties

**** Includes Imperial, Kern and San Luis Obispo counties

*** Includes Monterey, Kings, Tulare, Inyo, San Benito, Fresno, Mono, Santa Cruz, Merced, Madera, Stanislaus, Mariposa,Tuolumne, San Joaquin, Calaveras, Alpine, Amador, Mendocino, Lake, Colusa, Sierra, Glenn, Plumas, Humboldt,

Trinity, Tehama, Lassen, Shasta, Del Norte, Siskiyou and Modoc counties

**Includes Sacramento, Butte, El Dorado, Nevada, Placer, Solano, Sutter, Yolo and Yuba counties

Note: Clusters do not sum to total due to data suppression at the county level

Total Life Sciences Employment by Clusterin California, 2015

Sacramento Area**

2,5925,874

Ventura and Santa Barbara counties9,543

Riverside and San Bernardino counties11,009

Other Southern California****Other Northern California***

11,628San Diego County 38,694

Orange County 43,327Los Angeles County 57,174

Bay Area* 68,313

287,200TOTAL

CLUSTER

Life Sciences Employment vs.Other High-Tech Sectorsin California, 2015

Life sciencesindustry

Aerospace

Computer andperipheral

equipment mfg.

Motion pictures

Other electronicequipment mfg.

Internet, telecom-munications,

data processing

76,032

147,934

163,907

192,069

412,749

287,200

California Life Sciences Wagesby sector, 2015*

Academic ResearchBiopharmaceuticalsBiorenewablesMedical Devices,Instruments,DiagnosticsResearch &Development,Testing LabsWholesale Trade

TOTAL

AVG. WAGE TOTAL WAGES

$71,707

$157,352$72,831$95,946

$148,125

$116,484*

$2.98B

$7.55B$264M$7.15B

$10.3B

$33.5B

* Total average

$101,022 $5.2B

4

Attracting Major InvestmentsBecause California companies have such a strong trackrecord of translating lab science into products that helppatients and consumers, the state has long been a magnetfor investment. As in past years, California was the top statefor life sciences venture capital (VC) investment in 2016*with $4.4 billion: $3.3 billion in biotech and $1.1 billion inmedical devices. Massachusetts was second with $2.9 billion.The life sciences are second only to software in Californiafor VC funding.

Across biotech, investment declined in later-stage companies,but increased dramatically for seed stage startups. Medicaldevice investment also increased at seed and early stage.

VC investment in digital health in 2016* was significant at$1.6 billion, but declined from $2.1 billion in 2015. Still,California led the nation, more than doubling New York’s$730 million. These investments funded wearables andbiosensors, consumer health and wellness technologies,digital diagnostics, devices and therapies and other areas.

Mergers and acquisitions slowed considerably through earlySept. 2016 to 46, compared to 99 in 2015. Life sciences IPOsalso declined to three, compared to 25 in 2015. Thesenumbers reflect weak national M&A and IPO markets.

*2016 data based on projections from the first two quarters.

Massachusetts

New York

Pennsylvania

North Carolina

Texas

Michigan

Missouri

Minnesota

Kentucky

California

Top 10 States for Life SciencesVenture Capital Investment2014-2016*

2016*20152014

$4.43B

$2.94B

$352M

$240M

$237M

$153M

$143M

$102M

$97M

$94M

$4.51B

$2.70B

$173M

$334M

$249M

$234M

$112M

$152M

$135M

$12M

$3.90B

$2.25B

$47M

$286M

$181M

$269M

$129M

$37M

$235M

$19M

SOURCES: PricewaterhouseCoopers/National Venture Capital Association MoneyTree™ Report based on data from Thomson Reuters; Rock Health Digital Health Funding Database

2014 $731M $1.37B$781M$1.91B

2014 $218M $540M$345M$614M

2014 $380M $774M$1.27B$3.57B

2014 $56M$18M$157M$373M

2016* $534M $1.17B$465M$1.38B

2015 $524M $1.45B$550M$1.49B

2016* $77M $247M$368M$531M

2015 $245M $561M$406M$802M

2016* $462M $621M$1.89B$3.93B

2015 $319M $764M$2.06B$4.76B

2016* $24M $79M$603M$1.44B

2015 $23M $60M$377M$613M

See methodology for full sector definitions*2016 data based on projection from first two quarters

CaliforniaU.S.

Venture Capital Investment, Biotech and Medical Devicesby stage, U.S. and California, 2014-2016*

Seedstage

Earlystage

Expansionstage

Laterstage

MEDICAL DEVICESBIOTECH

$4.5B

$2.1B

SOURCES: PricewaterhouseCoopers/National Venture Capital Association MoneyTree™ Report based on data from Thomson Reuters; Rock Health Digital Health Funding Database

* 2016 data based on projection from the first two quarters

Digital Health VC InvestmentU.S. and California, 2015 vs. 2016*

$59.8B

$34.3B

$56.0B

$33.2B

$4.1B

$1.6B

2015 2016*

U.S. VC investment Calif. VC investment

TOTAL U.S. VC INVESTMENT TOTAL DIGITAL HEALTHVC INVESTMENT

2015 2016*

Note: The Los Angeles and Orange County region is comprised of Southern California(excluding the San Diego region), the Central Coast, and the San Joaquin Valley; theSacramento/Northern California region is comprised of Northeastern California; the SanDiego Region is comprised of the San Diego area; and the Bay Area and Silicon Valley regionis comprised of Northern California, the Bay Area and the Northern Coastline.

Life Sciences VC Investmentin California, by region, 2015 vs. 2016*

2016*2015

$7M

Los Angeles/Orange County

Sacramento/Northern Calif.

San Diego

Bay Area &Silicon Valley

$0

$244M$426M

$1.1B$614M

$3.1B$3.5B

5

Top 5 States Receiving NIH Grants2015 vs. 2016*

2015

California

Massachusetts

New York

Pennsylvania

North Carolina

Funding Awards

7,558

4,853

4,825

3,339

2,060

7,521

4,960

4,866

3,412

2,148

$3.40B

$2.35B

$1.99B

$1.47B

$972M

$3.58B

$2.52B

$2.15B

$1.54B

$1.07B

Note: Data excludes R&D contracts and projects funded throughthe American Recovery and Reinvestment Act

*2016 data reflect awards through October 3, 2016

SOURCE: National Institutes of Health

UC Berkeley

$112M

Kaiser Foundation Research Institute$62M

UC Irvine$125M

UC Davis$199M

USC$207M

Scripps Research Institute$211M

UCLA$379M

Stanford University

$400MUC San Diego

$424M

UC San Francisco$573M

Top 20 California OrganizationsReceiving NIH Funding2016*

California Institute of Technology

Sanford Burnham Prebys Medical Discovery Institute

Cedars-Sinai Medical Center

Beckman Research Institute/City Of Hope

J. David Gladstone Institutes

Salk Institute For Biological Studies

UC Santa Cruz

La Jolla Institute for Allergy and Immunolgy

Northern California Institute for Research and Education

RAND Corporation

$59M

$54M

$47M

$42M

$33M

$33M

$32M

$28M

$27M

$25M

11*3

2 3

4

4

2

22

4

SOURCE: Academic Ranking of World Universities, Shanghai Ranking Consultancy

*Stanford University, UC Berkeley, California Institute of Technology,UCLA, UC San Diego, UC San Francisco, UC Santa Barbara, USC, UC Irvine,UC Davis and UC Santa Cruz

SOURCE: NSF/NIH/USED/USDA/NEH/NASA; Survey of Earned Doctorates, 2014

Doctoral Recipients in Life Sciences DisciplinesTop 10 states, 2014

Total life sciences doctoral degrees

CaliforniaNew York

TexasMassachusetts

Pennsylvania

OhioMaryland

Florida

North CarolinaIllinois

California’s stellaracademic prowess was

on full display withmore than 1,300 lifescience doctoratesawarded in 2014.

1,318909904

667627

463459

407451

504

2016*

Academic ExcellenceCalifornia’s commitment to education is one of the enginesthat drive life sciences innovation. The state boasts 11universities in the world’s top 100, according to the ShanghaiIndex. California graduated more science and engineeringPhDs in 2014 than any other state with 4,984. New Yorkplaces second with 3,125.

Educational excellence attracts government investment.California continues to lead the nation in grants from theNational Institutes of Health (NIH): 7,521 awards for nearly$3.6 billion, 15.4 percent of total NIH grant funding in federalfiscal year 2016. Of the top 20 California institutions receivingNIH grants, seven are part of the University of California(UC) system.

California also led the country in Small Business InnovationResearch (SBIR) and Small Business Technology Transfer(STTR) funding, receiving 381 awards, totaling $176 million.

Number of Universities in the World Top 100Shanghai Index, 2016 rankings

CaliforniaNew YorkPennsylvaniaTexasIllinois

114443

* MassachusettsMarylandMinnesotaNew JerseyNorth Carolina

32222

Emerging Los AngelesFor years, the Bay Area and San Diego have been the twopoles of California’s entrepreneurial life sciences culture.Despite its size and strength in entertainment, agricultureand other sectors, Los Angeles has remained relativelyquiet. The city is starting to play catch-up and has madehuge progress in the past few years.

“We’re where San Francisco and San Diego were 20 yearsago,” says Shlomo Melmed, MD, executive vice presidentof Academic Affairs and Dean of the medicalfaculty at Cedars-Sinai.

Melmed points to several factors that may havepreviously slowed LA’s emergence: expensivereal estate, no central research hub, fewacademic medical centers. UCLA and USCgraduates have created startups – they’ve justdone it elsewhere.

“Los Angeles metro area produces more biologygraduates than any other city in America,” saysLlewellyn Cox, PhD, who founded Lab Launch, a biotechincubator network based in Monrovia. “But all these UCLAand USC spinouts seem to start up in San Francisco or SanDiego. Lab Launch was born out of the frustration ofwatching our friends leave town to start businesses.”

This disparity has not gone unnoticed. Led by SupervisorMark Ridley-Thomas, the Los Angeles County Board of

Supervisors recently earmarked $3 million to fund anotherbioscience incubator, LA BioMed.

Cox is excited by the general business dynamism in LosAngeles and sees life sciences startups plugging into LA’sexisting industries, such as agriculture.

“Look at cellular agriculture,” says Cox. “The technologyis biotech but once you have a product, you’re in the food

industry, your partners are going to be foodpeople.”

At a different level, Cedars-Sinai has been spinningoff companies from its research for more than 30years, developing a test to detect viruses in donatedblood, heart imaging software and therapies forinflammatory bowel disease. Their tech transferhas shown continuing growth.

Despite the relative dearth of startups, Los AngelesCounty employs around 20 percent of California’s

life sciences workforce. Both Cox and Melmed anticipatecontinued expansion.

“I think there’s going to be tremendous life scienceinvestment in population health management: software,accounting, patient management,” says Melmed. “Cancerwill drive it because of our large, aging population and highcancer incidence growth rate.”

Los Angeles Spotlight

SOURCES: Bureau of Labor Statistics Quarterly Census of Employment and Wages; 2012 Economic Census

* 2016 data based on projection from the first two quarters

SOURCE: Rock Health Digital Health Funding Database

Los Angeles County Digital HealthVenture Capital Investment2014-2016*

Investment

2015

2016*

$375M$68M

2014 $431M

Wholesale Trade12,858

Research &Development,Testing Labs

11,198

Medical Devices,Instruments, Diagnostics

11,867

Biopharmaceuticals8,177

Academic Research12,450

Biorenewables624

Total Life Sciences Employmentin Los Angeles County, 2015

TOTAL57,174

22%

14%

1%21%

20%

22%

Average Life Sciences Wagesin Los Angeles County, 2015

$73,368

Los Angeles County employed 57,174 in the life sciences fieldsin 2015, a 1.7 percent increase over 2014.

The average salary for a lifesciences worker in Los AngelesCounty is $73,368; Californiaaverage salary for life sciences

workers is $116,484.

Twenty percentof California’s287,200 life

sciences employeeswork in Los Angeles

County.

Top Los Angeles County NIH Funding2016* (excludes R&D contracts)

$760.1 million*Updated through Oct. 3, 2016SOURCE: National Institutes of Health

AWARDS FUNDING

TOTAL:

University of California, Los AngelesUniversity of Southern CaliforniaCalifornia Institute of TechnologyCedars-Sinai Medical CenterBeckman Research Institute/City Of HopeRAND Corporation

$378.8M$207.2M

$59.4M$47.4M$41.9M$25.4M

824400130105

9055

Shlomo Melmed, MD

Keeping California on TrackThe life sciences sector is an incredibly valuable asset forCalifornia. While the focus is life-saving medical technologies,that is hardly the limit of the industry’s impact. Researchersand companies are also working on new ways to providesustainable energy and increase the world’s food supply.

The life sciences directly employ more than a quarter of amillion people in California, providing economic benefits forcommunities and the state as a whole. These jobs are diffusedto communities throughout the state.

Factor in the investments life sciences companies and academicinstitutions attract – through venture capital, NIH grants andother sources – and we can see the immense value theseorganizations bring to our state.

However, as strong as the life sciences enterprise may be inCalifornia, we must never forget that this is an incrediblycompetitive sector. The state must continue its longstandingtradition of supporting world-class educational institutionswhile encouraging a more business-friendly environment.We must continue to nurture the biomedical innovation thathas made the Golden State a life sciences powerhouse.

We are committed to working with state and nationalpolicymakers, industry leaders, patient groups and otherstakeholders to ensure that patients have access to excellent,

affordable care. That means reducing the barriers that keepcutting-edge medicines away from patients, streamlining thetherapeutic pipeline and safeguarding intellectual property.

In addition, we must continue to support the Brain Researchthrough Advancing Innovative Neurotechnologies (BRAIN),Precision Medicine and other exciting research initiatives.By championing innovation, we can measurably improvehuman health and quality of life.

SOURCES: Bureau of Labor Statistics Quarterly Census of Employment and Wages;2012 Economic Census

AVG. ANNUAL SALARYCLUSTER

Average Life Sciences Wages by Clusterin California, 2015

Sacramento Area

$56,215$59,893

Ventura and Santa Barbara counties

$64,500Riverside and San Bernardino counties$73,368

Other Southern CaliforniaOther Northern California

$94,324

San Diego County$117,099

Orange County

$138,951

Los Angeles County

$162,226Bay Area$200,018

$116,484California average

Graphics and DesignPaul HornSpecial to CLSA

WritingJosh BaxtBaxt Communications

Economic AnalysisKristen Soderberg BernieManager, Health PolicyEconomicsPwC

Project Team

Will ZasadnyAssociate Director, CommunicationsCalifornia Life Sciences Association

Paula FinkbeinerManager, Pharmaceutical &Life Sciences AdvisoryPwC

Todd GillenwaterEVP, Advocacy & External RelationsCalifornia Life Sciences Association

Report AuthorsSara RadcliffePresident & CEOCalifornia Life Sciences Association

Peter ClaudePartner, Pharmaceutical &Life Sciences AdvisoryPwC

CLSA SAN DIEGO9191 Towne Centre Dr.,

Suite 450San Diego, CA

92122

© 2016 California Life Sciences Association

www.CALifeSciencesIndustry.com

Any trademarks included are trademarks of their respective owners and are not affiliated with, nor endorsed by, PricewaterhouseCoopers LLP, its subsidiaries or affiliates.

See methodology and more at

CLSA BAY AREA250 E. Grand Ave., Suite 26

South San Francisco, CA94080

CLSA WASHINGTON, D.C.1350 I St. NW, Suite 830

Washington, D.C.20005

CLSA LOS ANGELES605 E. Huntington Dr.,

Suite 103Monrovia, CA

91016

CLSA SACRAMENTO1201 K St., Suite 1840

Sacramento, CA95814

California Life Sciences Association (CLSA) is the state’slargest and most influential life sciences advocacy andbusiness leadership organization. With offices inSacramento, San Diego, South San Francisco, LosAngeles and Washington DC, CLSA works closely withindustry, government, academia and others to shapepublic policy, improve access to innovativetechnologies and grow California’s life scienceseconomy. CLSA serves biotechnology, pharmaceutical,medical device and diagnostics companies, researchuniversities and institutes, investors and serviceproviders throughout the Golden State. CLSA wasfounded in 2015 when the Bay Area BioscienceAssociation (BayBio) and the California HealthcareInstitute (CHI) merged. Visit CLSA atwww.califesciences.org, and follow us on Twitter@CALifeSciences, Facebook, Instagram, LinkedIn andYouTube.

PwC’s Pharmaceutical and Life Sciences practice, partof PwC’s Health Industries Group, is a leading advisorto public and private organizations across the entirehealth industries landscape. This group also includesPwC’s Health Research Institute, which provides newintelligence, perspectives, and analysis on trendsaffecting health-related industries. We provide industry-focused assurance, tax and advisory services to buildpublic trust and enhance value for our clients and theirstakeholders. More than 223,000 people in 157countries across our network of firms share theirthinking, experience and solutions to develop freshperspectives and practical advice. For more informationvisit: www.pwc.com/us/pharma.

Special Thanks to EvaluateEvaluateMedTech®www.evaluate.com